Table 2.

Differences in patient, clinical, tumor, and treatment-related characteristics by race among 482 patients diagnosed with ER/PR positive breast cancer in the Breast Cancer Care in Chicago study (2005–2008)

	N	White (N=264) %	Black (N=218) %
Age at diagnosis
<50	136	30	26
50–59	146	31	30
60–79	200	39	44
Education				<0.0001
<12	45	4	16
12	97	13	28
>12	338	82	56
Income				<0.0001
<20,000	96	10	32
<75,000	217	36	56
>75,000	156	49	12
Concentrated affluence				<0.0001
<1 SD below mean	26	1	11
Within 1 SD of mean	332	57	83
>1 SD above mean	124	42	6
Concentrated disadvantage				<0.0001
<1 SD below mean	91	33	1
Within 1 SD of mean	295	66	56
>1 SD above mean	96	1	43
Family History Breast Cancer
None	360	72	78
Weak	83	18	17
Strong	33	8	6
Parity				<0.0001
Parous	354	61	89
Nulliparous	128	39	11
Body Mass Index				<0.0001
Normal	166	48	18
Over	136	24	34
Obese	177	27	48
Insurance				<0.0001
None	36	4	11
Public	70	4	27
Private	376	92	61
Last clinical exam				0.0002
Within two years	371	83	69
Longer/never	111	17	31
Mode of detection				0.005
Screening	270	62	49
Symptoms	212	38	51
Tumor grade				0.09
Low	114	28	19
Moderate	204	41	44
High	142	28	31
Stage at diagnosis				0.16
0 (in-situ)	297	64	58
1	130	26	28
2–4	48	9	11
Radiation				0.05
Not recommended	113	22	26
Recommended1	79	13	20
Initiated2	290	65	54
Chemotherapy				0.005
Not recommended	249	58	44
Recommended1	39	7	9
Initiated2	194	35	46
Hormone Therapy				0.01
Not recommended	72	10	21
Recommended1	151	33	29
Initiated2	259	56	50

P-values >0.2 are suppressed.

¹Recommended but not initiated by the patient.

²Evidence that the treatment was initiated